9 On the 29th, "Arno Pharma," a portfolio company invested in by Detong Capital—the sub-fund backed by Yuanhe Chencun Management's flagship fund—was listed on NASDAQ, with the stock symbol: ANL.O.

Arnold Pharma is a global biopharmaceutical company at the clinical stage, with R&D and clinical operations centers located in both China and the U.S. Leveraging a dual approach of "collaborative innovation" and "internal R&D," the company has built a robust, globally diversified product pipeline. Notably: - AN2025 (buparlisib) has received FDA Fast Track designation and is currently being evaluated in a global, multi-center Phase III clinical trial. The drug, when combined with paclitaxel, holds promise as the first-in-class treatment for second-line recurrent or metastatic HNSCC patients who have failed PD-1 therapy. - AN0025 (palupiprant), an EP4 antagonist designed to modulate the tumor microenvironment for solid tumor treatment, is now advancing into a Phase Ib clinical trial—combining it with Keytruda® to treat patients with multiple advanced solid tumors. - AN4005, an independently developed oral small-molecule PD-L1 inhibitor, is currently undergoing Phase I clinical trials simultaneously in China and the U.S., aiming to establish its safety profile, tolerability, and the recommended Phase 2 dose (RP2D). Additionally, Arnold Pharma is actively pursuing a triple-combination therapy involving AN2025 (a PI3K inhibitor), AN0025 (an EP4 antagonist), and Roche’s anti-PD-L1 antibody (Tecentriq) for treating patients with solid tumors harboring PI3KCA mutations. This innovative regimen is currently in Phase I clinical trials in the U.S.

Arnold Pharma has assembled a seasoned management team and established a proprietary drug development platform, while also forging strategic partnerships with several globally leading pharmaceutical companies.

Arnold Pharma is committed to becoming an innovative R&D company dedicated to developing "globally novel" oncology drugs, bringing more effective treatment options to patients in China and around the world—and fulfilling our mission of transforming cancer into a chronic, or even curable, disease.